Trial Profile
A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Biotech Pharmaceutical
- 30 Aug 2023 Status has been changed to completed, as per Results published in the Journal of Clinical Oncology
- 30 Aug 2023 Results published in the Journal of Clinical Oncology
- 07 Jun 2022 Results (N=92) presented at the 58th Annual Meeting of the American Society of Clinical Oncology.